Acetylcysteine 10% ophthalmic solution recalled for sterility assurance concerns
Red Mountain Compounding Pharmacy is recalling Acetylcysteine 10% ophthalmic solution due to lack of sterility assurance identified during an FDA inspection. Approximately 494 patients received prescriptions for the product across seven states.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The product is classified as FDA Class II and involves a sterile compounded ophthalmic preparation. Lack of sterility assurance in eye drops poses a significant risk of infection, warranting a Severe classification per the rubric.
Plain-English summary
Red Mountain Compounding Pharmacy, operating as First Royal Care Co. LLC, is recalling Acetylcysteine 10% ophthalmic solution (eye drops). The FDA identified sterility assurance concerns during an inspection of the compounding facility.
The recalled product was distributed to approximately 494 patients who received prescriptions. Distribution occurred across Arizona, California, Florida, Minnesota, Montana, Texas, and Utah. All affected lots were within their expiration dates at the time of the recall.
Patients who have received this product should contact their healthcare provider or pharmacist for guidance. Healthcare providers should advise patients to discontinue use and obtain an alternative medication if appropriate.
The recalled product
- Product
- ACETYLCYSTEINE 10% OPTH SOLN, Red Mountain Compounding Rx
- Manufacturer
- First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy
- Category
- Drug — Compounded ophthalmic
- Hazard
- sterility-assurance
- compounding-error
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots within expiry
Distribution
Distributed in 7 states:
- AZ
- CA
- FL
- MN
- MT
- TX
- UT
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27